Last €1.90 EUR
Change Today -0.109 / -5.44%
Volume 0.0
HXXA On Other Exchanges
As of 5:53 AM 10/24/14 All times are local (Market data is delayed by at least 15 minutes).

idera pharmaceuticals inc (HXXA) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/24/14 - €5.00
52 Week Low
11/7/13 - €1.21
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

idera pharmaceuticals inc (HXXA) Related Businessweek News

No Related Businessweek News Found

idera pharmaceuticals inc (HXXA) Details

Idera Pharmaceuticals, Inc., a clinical stage biotechnology company, is engaged in the discovery and development of novel therapeutics that modulate immune responses through toll-like receptors (TLRs) in the United States. The company’s lead drug candidates in TLR program includes IMO-8400, which is in Phase 1/2 clinical trials for the treatment of various autoimmune diseases, such as moderate to severe plaque psoriasis, polymyositis, dermatomyositis, Waldenström’s macroglobulinemia, and diffuse large B-cell lymphoma; and IMO-9200 that is in preclinical studies that supports the submission of an investigational new drug application to the United States Food and Drug Administration. It is also involved in the initiation of research program that employs gene silencing oligonucleotides to inhibit the production of disease-associated proteins by targeting RNA. The company has license agreement with Merck KGaA to research, develop, and commercialize products containing its TLR9 agonists for the treatment of cancer; license and research collaboration agreement with Merck Sharp & Dohme Corp. to develop and commercialize TLR7, TLR8, and TLR9 agonists in the fields of cancer, infectious diseases, and Alzheimer’s disease; and an agreement with Abbott Molecular Inc. for the development of an in vitro companion diagnostic test. Idera Pharmaceuticals, Inc. was founded in 1989 and is based in Cambridge, Massachusetts.

18 Employees
Last Reported Date: 03/13/14
Founded in 1989

idera pharmaceuticals inc (HXXA) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $823.5K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $409.5K
Vice President of Clinical Development
Total Annual Compensation: $390.0K
Vice President of Development Programs & Alli...
Total Annual Compensation: $388.7K
Compensation as of Fiscal Year 2013.

idera pharmaceuticals inc (HXXA) Key Developments

Idera Pharmaceuticals Expands Pipeline by Initiating Clinical Development of Proprietary TLR Antagonist Candidate IMO-9200

Idera Pharmaceuticals, Inc. announced it has advanced IMO-9200 into Phase 1 clinical development following acceptance of an Investigational New Drug application by the U.S. Food and Drug Administration. In addition, the company announced the presentation of new data that showed IMO-9200 inhibited Toll-like receptor- (TLR-) mediated immune responses in multiple preclinical models at the 10th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS) in San Diego, California. These data support the development of IMO-9200, a synthetic oligonucleotide-based antagonist of TLRs 7, 8 and 9, as a potential treatment for autoimmune diseases in which TLRs are over-activated. Idera's pipeline of clinical-stage TLR antagonists also includes IMO-8400, the company's lead product candidate currently in development for genetically defined forms of B-cell lymphoma and rare autoimmune diseases. In two presentations at the OTS meeting, Idera scientists summarized the results of several preclinical studies of IMO-9200. Collectively, the data showed that IMO-9200 dose-dependently inhibited the induction of multiple inflammatory cytokines, including IL-12, IP-10, IFN-, IL-6, IL-1 and MCP-1, in cell-based assays, mice and non-human primates. In addition, data from a well-characterized preclinical model of lupus showed that IMO-9200 improved disease-associated parameters in MRL/lpr mice, with decreases in blood urea nitrogen levels, proteinuria, autoantibodies and kidney interstitial inflammation. Idera has evaluated IMO-9200 in additional autoimmune disease models, and plans to present data from these studies in the future. Idera plans to begin dosing of IMO-9200 in a Phase 1 clinical trial in healthy volunteers in the fourth quarter. In addition, the company plans to finalize a strategic assessment of potential indications for further clinical development of IMO-9200 by year end.

Idera Pharmaceuticals, Inc. Reports Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Idera Pharmaceuticals, Inc. reported unaudited earnings results for the second quarter and six months ended June 30, 2014. For the quarter, revenues were $38,000 against $29,000 a year ago. Loss from operations was $8,329,000 against $3,567,000 a year ago. Net loss applicable to common stockholders was $8,426,000 or $0.10 per basic and diluted share against $5,621,000 or $0.15 per basic and diluted share a year ago. For the six months, revenues were $41,000 against $36,000 a year ago. Loss from operations was $17,302,000 against $7,415,000 a year ago. Net loss applicable to common stockholders was $17,572,000 or $0.22 per basic and diluted share against $9,707,000 or $0.30 per basic and diluted share a year ago.

Idera Pharmaceuticals, Inc. and The Myositis Association Announce Collaboration for Advance Clinical Development of Novel TLR Antagonist, IMO-8400, for Treatment of Myositis

Idera Pharmaceuticals, Inc. and The Myositis Association announced a collaboration to advance a new potential treatment approach for polymyositis and dermatomyositis known as Toll-like receptor (TLR) antagonism. Under the collaboration, Idera and TMA will develop educational programs and resources for patients and healthcare providers, including interactive online chats, on TLR antagonism and opp ortunities to participate in upcoming clinical research. Idera plans to initiate a clinical trial of its investigational drug candidate IMO-8400, a first-in-class antagonist of TLRs 7, 8 and 9, in polymyositis and dermatomyositis by the end of 2014. Polymyositis and dermatomyositis are devastating, rare inflammatory myopathies that cause inflammation and progressive weakness in muscles. Polymyositis and dermatomyositis patients can develop serious disabilities, including loss of mobility, difficulty breathing and swallowing, and have an increased risk of certain cancers. Dermatomyositis is also accompanied by a purple or red skin rash. There are an estimated 15,000 polymyositis patients and 25,000 dermatomyositis patients in the U.S. alone. Both polymyositis and dermatomyositis have been designated as rare diseases by the U.S. Food and Drug Administration (FDA).


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HXXA:GR €1.90 EUR -0.109

HXXA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for HXXA.
View Industry Companies

Industry Analysis


Industry Average

Valuation HXXA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3,908.7x
Price/Book 3.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2,614.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IDERA PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at